Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 15.35% is 125% above its 5-year average of -62.27%, near the high end of its 5-year range (-128.23%–15.35%).
As of the fiscal period ended Tuesday, June 30, 2026. 413.54% above its 12-month average of -4.90%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 15.35%.
RETURN ON EQUITY (ROE)
15.35%
RETURN ON EQUITY (ROE) AVG TTM
-4.90%
RETURN ON EQUITY (ROE) AVG 3Y
-66.28%
RETURN ON EQUITY (ROE) AVG 5Y
-62.27%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+413.54%
CURRENT VS 3Y AVG
+123.16%
CURRENT VS 5Y AVG
+124.65%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-37.66%
median of 436 covered companies
CURRENT VS SECTOR MEDIAN
+140.76%
vs the sector median at left
Alignment Healthcare, Inc.
Market Cap
$1.76B
Return on Equity (ROE)
15.35%
TTM Avg
-4.90%
3Y Avg
-66.28%
5Y Avg
-62.27%
Market Cap
$1.78B
Return on Equity (ROE)
-54.96%
TTM Avg
-60.50%
3Y Avg
-51.30%
5Y Avg
-42.73%
Market Cap
$1.78B
Return on Equity (ROE)
N/A
TTM Avg
36.48%
3Y Avg
36.48%
5Y Avg
36.48%
Market Cap
$1.71B
Return on Equity (ROE)
-40.41%
TTM Avg
-45.75%
3Y Avg
-30.11%
5Y Avg
-18.95%
Market Cap
$1.83B
Return on Equity (ROE)
4.88%
TTM Avg
4.47%
3Y Avg
6.79%
5Y Avg
5.89%
Market Cap
$1.66B
Return on Equity (ROE)
-67.40%
TTM Avg
-53.05%
3Y Avg
2.62%
5Y Avg
2.10%
Market Cap
$1.87B
Return on Equity (ROE)
-40.09%
TTM Avg
4.56%
3Y Avg
-13.84%
5Y Avg
-2.18%
Market Cap
$1.65B
Return on Equity (ROE)
17.72%
TTM Avg
5.08%
3Y Avg
0.03%
5Y Avg
-3.88%
Market Cap
$1.65B
Return on Equity (ROE)
N/A
TTM Avg
-1058.20%
3Y Avg
-465.87%
5Y Avg
-348.95%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alignment Healthcare, Inc. (ALHC) | $1.76B | 15.35% | -4.90% | -66.28% | -62.27% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.78B | -54.96% | -60.50% | -51.30% | -42.73% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.78B | N/A | 36.48% | 36.48% | 36.48% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | -40.41% | -45.75% | -30.11% | -18.95% |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 4.88% | 4.47% | 6.79% | 5.89% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.66B | -67.40% | -53.05% | 2.62% | 2.10% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.87B | -40.09% | 4.56% | -13.84% | -2.18% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.65B | 17.72% | 5.08% | 0.03% | -3.88% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | N/A | -1058.20% | -465.87% | -348.95% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 12.01% | -4.52% | -16.89% | -11.36% |
ROE
15.4%
ROA
3.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 15.35% |
| 2026-03-31 | 9.57% |
| 2025-12-31 | -0.40% |
| 2025-09-30 | -12.86% |
| 2025-06-30 | -36.14% |
| 2025-03-31 | -83.81% |
| 2024-12-31 | -128.23% |
| 2024-09-30 | -125.84% |
| 2024-06-30 | -123.51% |
| 2024-03-31 | -120.10% |
| 2023-12-31 | -94.31% |
| 2023-09-30 | -83.71% |
| 2023-06-30 | -77.63% |
| 2023-03-31 | -65.57% |
| 2022-12-31 | -62.84% |
| 2022-09-30 | -51.62% |
| 2022-06-30 | -49.73% |
| 2022-03-31 | -61.11% |
| 2021-12-31 | -63.81% |
| 2021-09-30 | -55.23% |
| 2021-06-30 | -36.10% |
| 2021-03-31 | -19.68% |
| 2020-12-31 | -74.89% |
